![]() As a result, we are increasing our full year 2021 TEPEZZA net sales guidance to more than $1.625 billion. ![]() The TEPEZZA relaunch continued to outperform our expectations, driven by rapid patient starts, stronger patient demand and increasing prescriber base. We delivered strong results again this quarter across our business and continue to generate record performance for our key growth drivers TEPEZZA and KRYSTEXXA. Thank you, Tina, and good morning, everyone. These non-GAAP financial measures are reconciled with the comparable GAAP financial measures in our earnings press release and other filings from today that are available on our investor website at I will now turn the call over to Tim. In addition on today's conference call, non-GAAP financial measures will be used. You are cautioned not to place undue reliance on these forward-looking statements and Horizon disclaims any obligation to update such statements. Our actual results could differ materially due to a number of factors, including the risk factors and other information outlined in our latest Forms 10-K, 10-Q and any 8-Ks filed with the Securities and Exchange Commission in our earnings press release, which we issued this morning. After closing remarks from Tim, we'll take your questions.Īs a reminder, during today's call, we will be making certain forward-looking statements, including statements about financial projections, development activities, our business strategy and the expected timing and impact of future events. Liz will then provide a review of our R&D programs, followed by Paul who will discuss our financial performance and guidance in more detail. Tim will provide a review of the business, including our third quarter performance. On the call with me today are Tim Walbert, Chairman, President and Chief Executive Officer Paul Hoelscher, Executive Vice President, Chief Financial Officer Liz Thompson, Executive Vice President, Research and Development and Andy Pasternak, Executive Vice President, Chief Strategy Officer. ![]() Good morning, everyone, and thank you for joining us. Tina Ventura, Senior Vice President, Investor Relations. As a reminder, today's conference call is being recorded. Welcome to the Horizon Therapeutics Third Quarter 2021 Earnings Conference Call. Good morning, and thank you for standing by. Paul Hoelscher - Executive Vice President, Chief Financial OfficerĪndy Pasternak - Executive Vice President, Chief Strategy Officer Liz Thompson - Executive Vice President, Research & Development Tim Walbert - Chairman, President & Chief Executive Officer Tina Ventura - Senior Vice President, Investor Relations and Wyeth.Horizon Therapeutics Public Limited Company ( NASDAQ: HZNP) Q3 2021 Earnings Conference Call Novem8:00 AM ET From 1991 to 1998, he also held sales and marketing roles with increasing responsibility at G.D. From 1998 to 2001, Walbert served as director, CELEBREX North America, and arthritis team leader, Asia Pacific, Latin America and Canada, at G.D. ![]() From 2001 to 2005, he served as divisional vice president and general manager, immunology, at Abbott, now AbbVie, leading the global development and launch of the multi-indication biologic HUMIRA, and served as divisional vice president, global cardiovascular strategy. Before IDM, Walbert served as executive vice president, commercial operations at NeoPharm Inc., a public biopharmaceutical company. Before joining Horizon, he served as president, chief executive officer and director of IDM Pharma Inc., a public biopharmaceutical company which was acquired by Takeda America Holdings Inc., or Takeda, in June 2009. Tim Walbert joined Horizon in June 2008 as president and chief executive officer and has served as chairman of the company’s board of directors since 2010. Horizon Therapeutics - Pharmaceuticals Profile ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |